drugset / Trial / NCT02181764
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.
Timeline
- Start
- 2014-07
- Primary completion
- 2015-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Burosumab | Monoclonal antibody | 0.3 mg/kg | Subcutaneous |
| Subject | Burosumab | Monoclonal antibody | 0.6 mg/kg | Subcutaneous |
| Subject | Burosumab | Monoclonal antibody | 1 mg/kg | Subcutaneous |